Innovative Analytics
Your Date...Our Experience..Sound Decisions...
Fotolia_99629869_Subscription_XXL.jpg

Our Management Group

Patricia L. Ruppel, MPH, PhD
Co-founder, President & CEO
269.488.3200 x101
e-mail

Patty is the President, CEO, and cofounder of Innovative Analytics. Patty has over 30 years of experience in the pharmaceutical industry, primarily with Upjohn and Pharmacia. With undergraduate schooling in mathematics from Western Michigan University and graduate training as a biostatistician from the University of Michigan, she has provided statistical support for a broad range of scientific/clinical programs ranging from discovery research, to exploratory clinical development, to marketing registration efforts. Her most recent focus has been in the identification of biomarkers (including genomic, biochemical and imaging markers) and their optimization and validation in the clinical setting. She has been involved with several development programs and US/EU regulatory submissions for central nervous system, cardiovascular, inflammation, and urogenital drug applications, device applications, and orphan drug submissions. She also has several years of project and people management experience. Patty is an active member of the Drug Information Association (DIA) and the American Statistical Association (ASA).


James M. Dancy, BSE, MBA
Co-founder, Vice President & COO
269.488.3200 x102
e-mail

Jim is the Vice President, COO, and cofounder of Innovative Analytics.  Before Innovative Analytics, Jim held several key positions in data management, including the titles of Director of Clinical Database Operations (Pharmacia) and Director of Experimental Medicine Informatics (Pfizer).  While at Pfizer, Jim implemented a data warehouse to support clinical biomarker analysis, which earned a “Best Practices” award in 2003.  Jim holds an engineering degree from the University of Michigan and an MBA from Oklahoma University.  He is a member of the American Society for Quality (ASQ) and has been a Certified Quality Engineer (CQE) through that organization since 1991.  He is also a member of the Drug Information Association (DIA).


Gregory D. Elfring, MA, MS
Executive Director, SAS Programming
269.488.3200 x103
e-mail

Greg joined Innovative Analytics as a partner in 2004 to coordinate and implement the statistical services offered by the company. Greg has worked in the pharmaceutical industry since 1998 and has provided statistical support for all facets of product development, including discovery research, clinical development, regulatory affairs, and marketing. He has been recognized for his contributions in statistical design, analysis, and inference. Since joining Innovative Analytics, Greg has consulted and analyzed a number of thorough QT (TQT) studies to assess prolongation in the QT interval. He is also an experienced mathematics and statistics instructor and co-developer of educational software for college statistics courses. Greg received graduate degrees in mathematics from Indiana University and in statistics from The Ohio State University and is a member of the American Statistical Association.


Thomas H. Oliphant, MS , PhD
Executive Director, Clinical Statistics
269.488.3200 x104
e-mail

Tom joined Innovative Analytics as a partner in 2005 to coordinate and manage statistical support for clinical studies. Tom has over 18 years of experience in the pharmaceutical industry with Upjohn, Pharmacia, and Pfizer. He received undergraduate training in mathematics at Kent State University and graduate degrees in biometry and health information systems from the University of Minnesota. He has provided statistical support for registration and product support programs in the cardiovascular, critical care, anti-inflammatory, and infectious diseases therapeutic areas. Tom served as lead statistician for successful regulatory submissions in the United States, Europe, and Japan. For the 3 years before joining IA, he served as a director of clinical biostatistics at Pharmacia/Pfizer. He is a member of the American Statistical Association (ASA) and the International Biometric Society (IBS).


Kimberly T. Perry, MS, PhD
Director, Clinical Statistics
269.488.3200 x105
e-mail

Kim joined Innovative Analytics as a partner in 2006 to provide and coordinate statistical support for clinical studies and registration activities. Kim has over 25 years of experience in the pharmaceutical industry, primarily with Upjohn, Pharmacia, and Pfizer. She received undergraduate training and graduate degrees in biostatistics and mathematics from Western Michigan University. She has provided statistical support for registration and product support programs in the central nervous system and critical care therapeutic areas, as well as for device programs. Kim served as lead statistician for successful US and EU regulatory submissions. Before joining Innovative Analytics, Kim served as a director of clinical biostatistics for 5 years, followed by 3 years in pharmaceutical sciences as a statistical research fellow at Pharmacia/Pfizer. Kim is a member of the American Statistical Association (ASA) and a Trustee of the Kalamazoo Regional Education Service Agency Foundation.


Karen M. Tindall, BS, CCDM
Director, Clinical Data Management
269.488.3200 x221
e-mail

Karen is a certified clinical data manager with 10 years of experience in the bioscience industry (Pharmacia, Axio, and Icos) and joined Innovative Analytics in September of 2006.  She has extensive experience in managing clinical data management efforts for a variety of phase 1-3 studies and has implemented data management systems and created and maintained standards.  Karen’s primary interest is in optimizing data management processes through improved project management, data standards, and innovative solutions that will result in high-quality data and efficient timelines to database lock. 


Lillian Neff, BA
Executive Director, Medical Writing
269.488.3200 x111
e-mail

Lillian, Executive Director of Medical Writing, joined Innovative Analytics in January 2008. Lillian has over 30 years of experience in the pharmaceutical industry, including 27 years in industry at the legacy Pharmacia companies and 4 years of experience as a medical writer/consultant and president of The WRITE Phase, LLC, a company that she founded upon leaving Pharmacia. Her 27 years of experience in industry include several years in the laboratory and 5 years as a clinical research coordinator (during which she implemented and monitored clinical studies in depression, insomnia, and analgesia). However, her main focus while in industry, and before joining Innovative Analytics, has been medical writing. She has extensive (24 years) hands-on experience in writing all types of clinical drug development documents, from Investigational New Drug Applications (INDs) through registration documents in the Common Technical Document (CTD) format to advisory committee brochures to manuscripts. She has written documents in a variety of therapeutic areas, including cardiovascular diseases, central nervous system diseases, dermatology, oncology, and women’s health. Before leaving industry, Lillian was the global head of medical writing at Pharmacia and, thus, also brings both people and time management skills with her to Innovative Analytics. She has been a member of the American Medical Writers Association (AMWA) since 1984 and holds a medical writing certificate from that organization.